Search

This review summarizes recent advancements in FeSe and related systems. The FeSe and related superconductors are currently receiving considerable attention for the high Tcs observed and for many similar features to the high Tc cuprate superconductors. These similarities suggest that understanding the FeSe based compounds could potentially help our understanding of the cuprates. We shall first review the common features observed in the FeSe-based system. It was found that with a careful control of material synthesizing processes, numerous rich phases have been observed in the FeSe-based system. Detailed studies show that the Fe-vacancy ordered phases found in the FeSe based compounds, which are non-superconducting Mott insulators, are the parent compounds of the superconductors. Superconductivity emerges from the parent phases by disordering the Fe vacancy order, often by a simple annealing treatment. Recent high temperature X-ray diffraction experiments show that the degree of structural distortion associated with the disorder of Fe-vacancy is closely related to volume fraction of the superconductivity observed. These results suggest the strong lattice to spin coupling are important for the occurrence of superconductivity in FeSe based superconductors.

Power distribution system resilience is not considered in traditional planning of distributed generator (DG), which leads to severe power outages and economic losses during extreme weather event. To address this issue, this paper proposes a resilience-oriented comprehensive planning strategy of DG in power distribution system. The problem is formulated as a two-stage stochastic mixed-integer second-order cone programming (SMISOCP). The objective of the first stage is to determine the number, location and capacity of DG and obtain the economic cost of power distribution system. The second stage minimizes the resilience cost under uncertain failure scenarios. First, sufficient failure scenarios are generated by the Monte Carlo method. Then the failure scenarios are reduced to the most representative scenarios by using the K-means clustering algorithm to reduce computational burden. Finally, the two-stage SMISOCP is solved based on the reduced failure scenarios. The simulation results of the IEEE 33-bus test systems illustrate the effectiveness of the proposed two-stage strategy.

The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%-100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confidence interval, 52%-94%) patients with genotype 3 infection. Most adverse events were of mild or moderate severity. The most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash. One patient (1%) with genotype 1a infection discontinued all study drugs due to an adverse event (irritability).Retreatment of patients who previously failed direct-acting antiviral-based therapies with sofosbuvir-velpatasvir plus ribavirin for 24 weeks was well tolerated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection. (Hepatology 2017;66:1083-1089).

Background A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1. Methods This phase 3, open-label, single-arm study at 17 sites in the United States enrolled patients with HCV of any genotype and HIV-1 coinfection, including those with compensated cirrhosis. All patients received sofosbuvir-velpatasvir once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Efficacy and safety were assessed in all patients receiving at least 1 dose of treatment. Results Of 106 patients, 91 (86%) were men, 48 (45%) were black, and 19 (18%) had cirrhosis. SVR12 was achieved by 101 of 106 (95% [95% confidence interval {CI}, 89%-99%]) patients: 74 of 78 (95% [95% CI, 87%-99%]) with genotype 1; all 11 (100% [95% CI, 72%-100%]) with genotype 2; 11 of 12 (92% [95% CI, 62%-100%]) with genotype 3; and all 5 (100% [95% CI, 48%-100%]) with genotype 4. All 19 patients with cirrhosis had SVR12. Two patients relapsed, 2 were lost to follow-up, and 1 withdrew consent. Two discontinued treatment due to adverse events and 2 had serious adverse events. The most common adverse events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%). Conclusions Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rates of SVR12 in patients coinfected with HCV and HIV-1. Clinical Trials Registration NCT02480712.

Supplemental material, DS_10.1177_0022034520968750 for Carcinogenesis of Male Oral Submucous Fibrosis Alters Salivary Microbiomes by M.Y. Chen, J.W. Chen, L.W. Wu, K.C. Huang, J.Y. Chen, W.S. Wu, W.F. Chiang, C.J. Shih, K.N. Tsai, W.T. Hsieh, Y.H. Ho, T.Y. Wong, J.H. Wu and Y.L. Chen in Journal of Dental Research

Sofosbuvir-velpatasvir is approved for the treatment of chronic hepatitis C virus (HCV) infection. In this single-arm, open-label, phase 3, deferred treatment study, we investigated the efficacy and safety of sofosbuvir-velpatasvir among patients randomized to the placebo group in the ASTRAL-1 study. Patients received sofosbuvir-velpatasvir (400/100 mg) once daily for 12 weeks. The primary efficacy endpoint was the proportion of patients with sustained virologic response 12 weeks after the end of therapy (SVR12). The primary safety endpoint was any adverse events (AEs) leading to the permanent discontinuation of study drug. Overall, 108/111 (97%, 95% confidence interval [CI], 92%-99%) achieved SVR12, and only one patient had virological failure. SVR12 was achieved by 61/63 (97%, 95%CI, 89%-100%) genotype 1 patients, 20/20 (100%; 95%CI, 83%-100%) with genotype 2, 19/19 (100%; 95%CI, 82%-100%) with genotype 4 and 8/9 (89%; 95% CI, 52%-100%) with genotype 6. All (19/19; 95%CI, 82-100) patients with cirrhosis and all (31/31, 95%CI, 89-100) with prior treatment experience achieved SVR12. The safety profile during treatment was similar to that observed in patients receiving placebo treatment. The most common AEs were headache, fatigue and nausea. One patient (1%) discontinued treatment due to an AE of gallbladder carcinoma, which was not considered related to treatment. Of five reported serious AEs, none were considered related to study drug. Sofosbuvir-velpatasvir for 12 weeks was effective and well tolerated among untreated and previously treated patients with HCV genotype 1, 2, 4 or 6 infection, including those with compensated cirrhosis (ClinicalTrials.gov NCT02346721).

Traditionally, the process capability index is developed assuming that the process output data are independent and follow normal distribution. However, in most environmental cases, the process data have more than one quality characteristic and exhibit property of autocorrelation. We propose two novel multivariate process capability indices for autocorrelated data, NMACp and NMACpm, for the nominal-the-best case. For the smaller-the-better case, Γ(0) is used to modify the ND index and a new multivariate autocorrelated process capability index NMACpu is derived. Furthermore, a simulation study is conducted to compare the performance of the various multivariate autocorrelated indices. The simulation results show that the actual nonconforming rates can be correctly reflected by our proposed indices, which outperform the previous Cpm, MCp, MCpm, NMCp, NMCpm, and ND indices under different time series models. Thus, our proposed capability indices can be used in evaluating the performance of multivariate autocorrelated processes. Finally, a realistic example in hydrological application further demonstrates the usefulness of our proposed capability indices. Copyright © 2013 John Wiley & Sons, Ltd.

Background Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes. We conducted an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HCV infection. Methods We enrolled treatment-naive patients with and without compensated cirrhosis at 15 sites in Canada. All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-based ribavirin for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Secondary endpoints included evaluation of baseline and treatment-emergent drug resistance. Results Of the 111 patients enrolled, 105 (95%) had subtype 3a HCV and 39 (35%) had compensated cirrhosis. SVR12 was achieved by 99 of 111 patients (89%; 95% confidence interval, 82%-94%). Of the 39 patients with cirrhosis, 31 (79%) achieved SVR12, compared with 68 of 72 (94%) patients without cirrhosis. No treatment-emergent resistance mutations occurred in those who failed treatment. One patient discontinued treatment due to liver cancer and died 22 days after treatment discontinuation. The most common adverse events were fatigue (51%), headache (36%), and nausea (23%). Conclusions In this multicenter trial involving treatment-naive patients with genotype 3 HCV, 12 weeks of ledipasvir-sofosbuvir provided a high level of SVR in those without cirrhosis. Clinical Trials Registration NCT02413593.

Background & Aims Treatment with direct-acting antiviral (DAA) agents can reduce Model for End-Stage Liver Disease and Child-Pugh-Turcotte (CPT) scores in patients with decompensated cirrhosis caused by hepatitis C virus. However, many of these patients still die or require liver transplantation. We collected data on baseline features of patients and aimed to develop a scoring system to predict response to DAA therapy. Methods We performed a retrospective analysis of data from 4 trials on the effects of sofosbuvir-based therapy in patients with hepatitis C virus–associated decompensated cirrhosis (502 of CPT class B and 120 of CPT class C). In these trials, patients were given 12 or 24 weeks of treatment with ledipasvir, sofosbuvir, and ribavirin or velpatasvir, sofosbuvir, and/or ribavirin, or 48 weeks of treatment with sofosbuvir and ribavirin. We collected demographic, clinical, treatment response, and laboratory data from patients and tested their associations with patient outcomes at 36 weeks. The primary outcome was factors associated with reduction of CPT score to class A. Results The presence of ascites or encephalopathy, serum level of albumin 25 kg/m2 were associated with an increased risk of not achieving a reduction in CPT to class A, independent of sustained viral response to therapy. Serum level of albumin Conclusions We identified 5 baseline factors (body mass index, encephalopathy, ascites, and serum levels of alanine aminotransferase and albumin) associated with a reduction of CPT score to class A in patients with hepatitis C virus–associated decompensated cirrhosis receiving DAA therapy. We developed a predictive score using these factors, called the BE3A score, which can be used as a shared decision-making tool, quantifying the potential benefits of DAA therapy for patients with decompensated cirrhosis.

Solid solutions of the GdFeO 3 –GdInO 3 system were prepared at 1550 °C by ceramic powder processing. The formulated composition was Gd(Fe 1− x In x )O 3 (GFI) with the indium contents at x = 0, 0.25, 0.5, 0.75, and 1.0. A stable phase of Gd(Fe 1/3 In 2/3 )O 3 in our system was identified by X-ray diffraction and phase composition analysis. Multi-phase morphologies were observed for GFI bulks with x = 0.5 and 0.75. Dielectric and electrical properties of the GFI bulks were investigated. The addition of 25% In 3+ in GdFeO 3 had an obvious enhancement in polarization and led to an elevated resonance frequency. Dielectric properties of GFI bulks except GdInO 3 were strongly dependent upon the test frequency, which corresponded to the response of polarization mechanism. GdInO 3 displayed as a stable dielectric, which was frequency- and temperature-insensitive. GdInO 3 was thermally activated and became leaky until above 600 °C.

Ni–SiC composite coatings were electroplated from a nickel sulphamate solution with a SiC suspension, with and without the addition of monovalent thallium ions. Without thallium ions, the incorporated SiC particles did not modify the columnar grain structure of the nickel matrix. Conversely, the nickel matrix exhibited an equiaxed grain structure; meanwhile, the amount of codeposited SiC was markedly increased by adding thallium ions to the solution. Additionally, the density of lattice defects associated with nickel grains substantially decreased when the columnar grains were replaced by equiaxed grains. These distinct grain structures associated with the various coatings were discussed in terms of the inhibition of nickel electrocrystallization by thallium ions as well as the absorption and reduction of the various ionic species absorbed on the surface of the SiC particles.

Background The once-daily fixed-dose combination tablet of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) was evaluated for the treatment of genotype 1–6 HCV infection in four phase 3 studies in patients with and without compensated cirrhosis. This analysis describes the safety of SOF/VEL/VOX across 4 Phase 3 studies. Methods Treatment-emergent adverse events (AEs) and laboratory abnormalities were assessed in patients who received SOF/VEL/VOX or placebo for 12 weeks (POLARIS-1), SOF/VEL/VOX or SOF/VEL for 12 weeks (POLARIS-4), or SOF/VEL/VOX for 8 weeks or SOF/VEL for 12 weeks (POLARIS-2 and POLARIS-3). SAEs and deaths were followed until post-treatment Week 24. Data were pooled by treatment regimen. Results 1056 patients were treated with SOF/VEL/VOX for 8 (n=611) or 12 (n=445) weeks, 700 received SOF/VEL for 12 weeks. 38% had compensated cirrhosis, 28% had a BMI≥30 kg/m2, 36% were female, and 12% were ≥65 years old. AEs are presented in the table. Two deaths were reported, one illicit drug overdose and one attributed to hypertension (on post-treatment Day 76), neither were related to treatment. SAEs and discontinuations were more frequent in the placebo group and occurred with similar frequency in the other groups; none were related to study treatment. Headache, fatigue, nausea, and diarrhoea were the most common AEs. Mild diarrhoea and nausea occurred more frequently in the SOF/VEL/VOX groups. Overall, 5.1%–6.6% of patients who received SOF/VEL/VOX or SOF/VEL had Grade 3 or 4 laboratory abnormalities. Among patients receiving VOX, one patient each had a Grade 3 elevation in ALT and bilirubin (table 1). Conclusions SOF/VEL/VOX for 8 or 12 weeks in the POLARIS studies was well tolerated with a low frequency of Grade 3 or 4 AEs, SAEs, and AEs leading to discontinuation. The frequency of AEs in the SOF/VEL/VOX groups was similar to SOF/VEL and placebo groups, with higher rates of mild diarrhoea and nausea compared to SOF/VEL. References 1. Time to get control. A review of the care received by patients who had a severe gastrointestinal haemorrhage. NCEPOD 2015. 2. Shaheen AAM, Kaplan GG, Myers RP.Weekend versus weekday admissions and mortality from gastrointestinal haemorrhage caused by peptic ulcer disease. Clinical Gastroenterology and Hepatology2009;7:303–310.

Poster Presentations - Preliminary results of retrospective single center experience: no. SAT-279

YBa 2 (Cu 1− x M x ) 4 O 8 (MFe, Co, Ni, Zn and Ga; 0 ⩽ x ⩽ 0.05) have been investigated by means of X-ray diffraction, electrical-resistivity and magnetic-susceptibility measurements. X-ray-diffraction patterns show that all samples studied contain the nearly single 124 phase. They exhibit an orthorhombic-to-tetragonal structural transition at about x = 0.03 for MFe and Co; and at x = 0.04 for MGa; while the structure remains orthorhombic at x = 0.05 for MNi and Zn. These results suggest that Fe, Co and Ga substitute preferentially for [Cu(1)] sites, and the Ni and Zn prefer to occupy the [Cu(2)] sites. The initial depression rates of T c0 (temperature of zero resistance) with increasing doping concentration for various dopants are 16.85, 8.4, 23.75, 12 and 3.9 K/at.% for MFe, Co, Ni, Zn and Ga, respectively. Effective magnetic moments of YBa 2 (Cu 0.97 M 0.03 ) 4 O 8 are 5.63, 3.91 and 3.37 μ B for MFe, Co and Ni, respectively. In addition, the similarities and differences between YBa 2 (Cu 1− x M x ) 4 O 8 and YBa 2 (Cu 1− x M x ) 3 O 7− y are discussed.

The Extended Protocol Validation Development System (EPVD) is extended on PVD [1]. The PVD provides an interactive protocol specification and validation software environment on finite state machine (FSM) model. EPVD extends an Estelle environment into PVD, then provides the specification and validation of communication protocol in Estelle formal specification. It provides a graphic-interface for user to specify the modules and transitions of communication protocol. By ultilizing our developed intra-module combination/validation technique, we can easily combine and validate these trnasitions. A FSM and the logical correctness of associated these transitions can also be found as well. The inter-module combination/validation algorithm is developed to combine and to validate the FSMs of module, and in turn, is used to find a FSM and the logical properties of their communications EPVD implements those approaches with several tools. Users could use these tools to specify a communication protocol with either FSM model or Estelle model, and to validate the intra-entity and inter-entity communications. This system has been used to design and to validate an ABP specification [4], and the result is to be reported.

The Protocol Validation Development system (PVD) is based on the Finite State Machine (FSM) model to provide an interactive protocol specification and validation software environment, It is used to help the protocol designer to design and validate communication protocols. The PVD supports a specification tool to specify two processes FSM communication protocols by using graphic schema as the protocol input stage, and integrates several tools that implement two validation methods of the conventional exhaustive state exploration [9, 12] and the random walk state exploration [10, 11]. By the utilization of these validation tools to analyze the given protocol, one can find out whether the communication protocol meets the logical correctness properties , such as deadlock freeness, unspecified reception freeness and channel overflow freeness. The PVD system utilizes the relational approach [7] to control and manage its internal data representation. This system has been used to design and validate a version of the CCITT transport class 2 protocol [3]. The validation result is to be reported.

Since 1978, when exhaustive reachability analysis technique was proposed the problem of state space explosion came out. Thereafter, in the past decade, many proposals were introduced to solve this problem. Nevertheless, all of them were based on the concept of asynchronous exploration . In this paper we will propose another improved technique — Reduced Stable State Pair (SSP) Exploration , that is based on the concept of synchronous exploration . It uses the responsibility transfer rules to reduce redundant explorations and comparison times which are caused by asynchronous exploration . Thus, we can reach the objective of saving memory storage space and execution time. In this technique, we can separate the whole exploration algorithm into two parts. The first one is synchronous exploration that plays the role of main architecture of the whole algorithm and attempts to explore all stable state pairs . If it meets a collision stable state pair when proceeding with exploration, it will call the second procedure — asynchoronous fair progree exploraton to explore those unstable states . Owing to the independence of both storage and reference of data between each asynchronous fair progress exploration, there will be no problem of state space explosion caused by accumulating of recorded data.

A fault tolerant modular architecture for generalized Boolean n-cube network is presented. In this approach, each module consists of 2 α original processors (nodes) and one spare processor (node), for 0≤ α ≤n-1. The spare processor can replace each of the original processors within the same module. Thus, each module can tolerate one fault and the system can tolerante several faults if they are located in different modules. And then, a distributed fault tolerant routing algorithm is proposed. When a message destined to a faulty processor will be delivered to the spare that replaces the faulty processor. Finally, we show that the architecture can achieve very high reliability.

The characteristics of high-temperature processed thin-film transistors (TFT's) with/without plasma hydrogenation under the stress condition of V/sub ds/=-15 V and V/sub gs/=0 V have been investigated and compared. It is found that, after stress, the subthreshold swing is greatly improved for unhydrogenated TFT's but not for hydrogenated TFT's. Also, the off-state current is deteriorated for unhydrogenated TFT's but, on the contrary, it is improved for hydrogenated TFT's. A model that takes the effect of hydrogen passivation into account is proposed to interpret the anomalous behavior of TFT's under electric stress.

In this study, a divided ground structure is proposed for the C-patch antenna. The separated ground structure of the C-patch antenna exhibits some characteristics than are similar to that of a dipole antenna. However some of the characteristics of the antenna are still strongly affected by the loaded capacitor. With hybrid characteristics. this type of antenna is called a C-patch dipole antenna. The range of the operating frequency variation for the C-patch dipole antenna is small compared with that of the C-patch antenna. However, the antenna efficiency of the C-patch dipole antenna is better than that of the C-patch antenna. As the size of antenna reduces, the radiation efficiency of the C-patch dipole antenna increases accordingly if designed properly. A bent strip antenna is presented in this paper to demonstrate the effect of the C-patch dipole antenna. This bent antenna exhibits characteristics of dual polarization that could be used as a polarization diversity antenna for low profile communication.

It was found that an antenna strip with loaded capacitors, i.e., a C-Patch strip, could operate with electrical small radiator. A comparison of the measurements shows that there is a clear antenna gain difference between the high frequency and low frequency regions. Although the antenna gain does peak up at the tuned frequency, one will wander whether it could be improved more A spiral antenna is a broadband antenna that has been widely used in many applications. A combination of the antenna strip with the spiral shapes could bring the high gain antenna region down to the appropriate frequency. In this paper, the effort of combining the C-Patch technology with a dual spiral antenna will be presented.

A spiral shape C-patch antenna is presented. A slot between the feed and ground plane is used as an equivalent capacitor for the C-patch antenna. By controlling the size of the slot, the loaded capacitance can be changed. A high gain antenna of size less than 8 cm /spl times/ 8 cm that operates at 174 MHz is needed for automotive applications. A spiral C-patch antenna is used for this design. The original operating frequency of the spiral C-patch antenna is 420 MHz. By introducing the slot between the feed structure and the ground plane, the operating frequency of the spiral C-patch can be reduced to 170 MHz or less. The gain and efficiency of the antenna is qualitatively assessed using communication quality and radiated power. By experiment, the efficiency of this spiral C-patch antenna is shown to be much higher than a 45 cm commercial dipole antenna.

Previously, a nonlinear passivity control has been proposed for a discrete-time (neutrally) stable bilinear system. However, the decay rate of the closed-loop system is not exponential. In this paper, a new nonlinear control is suggested to achieve exponential decay rate. It is also shown that the new control is robust against small parametric uncertainties.

The paper presents the design and implementation of a switching-mode power amplifier for shaker armature excitation. First, the dynamic model of a current-source-driven shaker system is derived. Then a novel current-controlled PWM scheme is proposed for performing the switching control of inverter. To obtain good reference-current tracking-control characteristics over a wide frequency range, the feedback-current controller is augmented with a command-feedforward controller and a robust disturbance-feedforward controller. In the design of the disturbance-feedforward controller, the disturbance observer and robust-control technique are developed to make it practically feasible and have robust control performance. The design of the proposed controller is described in detail and practical limitations and the implementation of the current controller are discussed. Some measured results are provided to demonstrate the performance of the developed switching-mode power amplifier.

Heteroepitaxial growth of InP on Si with an intermediate GaAs buffer layer by low-pressure metalorganic vapor phase epitaxy is reported. Single-crystal InP epilayers with specular surfaces can be reproducibly obtained. The uniform composition of this heterostructure was identified by the Auger depth profile. The best room-temperature electron mobility of the undoped InP epilayer can reach 3250 cm 2 /V·s with a carrier concentration of 1×10 15 cm −3 . It was found that the InP electron mobility is critically dependent on the growth temperature. The 77 K photoluminescence (PL) of the InP layer exhibits a strong near-band-edge emission. No evident shift in PL peak energy for the InP/GaAs/Si sample compared with that for the InP homoepitaxial sample was first observed in this study. An evident effect of the GaAs buffer-layer thickness on the InP optical quality is also demonstrated.

The levels of 11-deoxy-13,14-dihydro-15-keto-115, 16ξ-cyclo PGE 2 (bicyclo PGEM), 13,14-dihydro-15-keto PGF 2α (PGFM), cortisol and prolactin were measured by radioimmunoassays in five serial plasma samples collected from fourteen patients undergoing falope ring application and three patients undergoing tubal electrocautery. Bicyclo PGEM, PGFM and cortisol levels were unchanged regardless of the type of tubal occlusion procedure or the type of anesthesia administered (7 received general and 10 local anesthesia). Prolactin levels, on the other hand, markedly increased. The increase was greatest in women that received general anesthesia. The lack of change in bicyclo PGEM and PGFM in peripheral plasma would suggest a local transfer of PGs produced by injured tubal tissue to other parts of the tube and the uterus resulting in increased contractions and pelvic pain.

A technique was presented to prepare isolated epithelial cells from rabbit's intestine. The cells consumed oxygen at a rate of 3.25±0.185 ml/gm dry weight/hour and produced CO 2 at a rate of 2.10±0.334 ml/gm dry weight/hour. The respiratory quotient was 0.645. The isolated epithelial cell suspension rapidly accumulated 3MG and L-tyrosine. A peak of accumulation was reached after a 10 minute incubation. The concentration was greater at 36°C than at 25°C and 20°C and was inhibited in the presence of 2,4-DNP and L-phenylalanine.